The treatment was developed by Urotronic, a medical technology company that specializes in treating urological conditions, and uses a drug-coated balloon to treat benign prostatic hyperplasia by dilating the urethra and allowing improved urine flow, Urotronic said in a July 11 news release.
The system results in substantial, immediate improvements in BPH patient symptoms and functions that was maintained throughout the four-year follow-up period, according to findings from clinical trials.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
